A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910